Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib in Unresectable, Metastatic Biliary Tract Carcinoma

NCT01149122 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01149122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01149122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib in Unresectable, Metastatic Biliary Tract Carcinoma
Lead sponsor
Samsung Medical Center
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2009
Completion date
June 30, 2012
Enrollment
266 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable, metastatic biliary tract carcinoma